Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals is a global biopharmaceutical company that produces Soliris® (eculizumab), a first-in-class terminal complement inhibitor discovered, developed and marketed exclusively by Alexion.

In March 2007, the U.S. Food and Drug Administration (FDA) approved Soliris as the first treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH).